CymaBay Therapeutics Investor Relations Material

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. It is developing seladelpar, which is in Phase IIb clinical trials for the treatment of primary biliary cholangitis (PBC) and in Phase II trials for the treatment of bile acid diarrhea; MBX-2982 that is in preclinical development stage; and MBX-8025 to treat homozygous familial hypercholesterolemia. The company was founded in 1989 and is headquartered in Newark, California.